Normally, negotiations to use drugs in preclinical studies and clinical trials can take as long as 18 months. But the National Cancer Institute’s (NCI) new drug formulary will allow investigators at NCI-designated cancer centers quicker access to approved and investigational agents, helping make more effective treatments available sooner.
The NCI Formulary, a public-private partnership between NCI and pharmaceutical and biotechnology companies, is one of NCI’s efforts in support of the Cancer Moonshot (ex-Vice President Biden’s call for greater collaboration and faster development of new therapies). The formulary enables NCI to act as an intermediary between investigators at cancer centers and participating pharmaceutical companies, streamlining arrangements for access to and use of drugs.
The formulary launched with 15 targeted agents from 6 pharmaceutical companies: Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Kyowa Hakko Kirin, Loxo Oncology, and Xcovery Holding Company LLC.